Brahmi, Shankhpushpi, and Vacha for Brain Health Across the Lifespan

Executive summary

Among the three herbs requested, Brahmi as Bacopa monnieri has the strongest modern evidence base, especially for adult memory/attention, older-adult cognitive performance, and stress/anxiety-related outcomes. Human randomized controlled trials have repeatedly used standardized Bacopa extracts in the 300–450 mg/day range for 6–12 weeks or longer, and systematic reviews/meta-analyses generally find small-to-moderate benefits in memory consolidation, delayed recall, attention speed, and reaction time, though not every domain improves in every trial. Pediatric evidence for ADHD-related symptoms is promising but still limited and mixed: one open-label study found improvement with 225 mg/day for 6 months, while a later randomized trial in boys aged 6–14 years found benefits mainly in cognition, mood, and sleep, with less convincing effects on core behavioral symptoms. For autism spectrum disorder, no human Bacopa trial was identified; the evidence is currently preclinical only.

Shankhpushpi is not one plant in actual practice. In the official Ayurvedic Pharmacopoeia of India, Shankhapushpi is standardized as Convolvulus pluricaulis Choisy, but the same monograph explicitly notes that in some parts of India Clitoria ternatea and Evolvulus alsinoides are also used as Shankhapushpi. This matters because many experimental studies, and even some product claims, mix these species together. Modern evidence is therefore best read species-by-species, not under the umbrella name alone. The strongest data are preclinical: animal and in vitro studies support anxiolytic, memory-enhancing, antioxidant, cholinergic, and neuroprotective effects for C. pluricaulis, E. alsinoides, and C. ternatea. Human evidence is thin. For C. pluricaulis, I found a small single-arm clinical appraisal in healthy volunteers aged 16–25 years reporting improved memory after 2 months of Bhāvita Śaṇkhapuṣpī tablets, but this is not a randomized placebo-controlled trial. I did not identify robust human trials for ADHD, ASD, or dementia using isolated C. pluricaulis, E. alsinoides, or C. ternatea.

Vacha is even more species- and regulator-sensitive. In Ayurveda, official Vacha is Acorus calamus L., whereas much of the Chinese neuropharmacology literature uses Acorus tatarinowii Schott—a name that Kew currently treats as a synonym of Acorus verus. The main bioactive and toxicologically important constituents are α-asarone and β-asarone. Modern evidence for cognition and anxiety is again mostly preclinical, with one older non-randomized human study in generalized anxiety disorder using 500 mg twice daily for 60 days and reporting improvement. For dementia, the human evidence I found concerns a herb pair (Polygala tenuifolia + Acorus tatarinowii), not isolated Vacha: a 2024 meta-analysis of 16 RCTs in Alzheimer disease suggested possible additive benefits when used with conventional treatment, but the certainty was very low to low, and the effect of Acorus alone cannot be separated. Safety is the biggest issue: the U.S. prohibits added calamus, calamus oil, or calamus extract in food; EMA warns that α- and β-asarone should be minimized because of toxicity concerns; and commercial positioning of Acorus calamus in consumer “brain booster” products is therefore far more difficult than for Bacopa.

The bottom line for practical formulation is straightforward. If a product is being built for evidence-backed cognitive support, Bacopa should be the lead herb. Shankhpushpi can be included only if the species is named on the label, with claims limited to traditional use unless the manufacturer has species-specific clinical evidence. Vacha should generally be excluded from mainstream retail/export formulas, especially for the U.S. and EU, because the toxicology/regulatory burden is disproportionate to the current human efficacy evidence.

Botanical identity and classical Ayurvedic context

The first scientific problem is nomenclature. In modern phytotherapy and supplement markets, “Brahmi” usually means Bacopa monnieri, but authoritative sources note that the traditional name has also been used for Centella asiatica or for both plants in overlapping Ayurvedic usage. The official Ayurvedic Pharmacopoeia of India monograph identifies Brahmi (whole plant) as Bacopa monnieri (L.) Wettst.; Kew likewise recognizes Bacopa monnieri as an accepted species.

For Shankhpushpi, the official Ayurvedic Pharmacopoeia monograph defines the drug as Convolvulus pluricaulis Choisy and describes it as a Medhya and Rasayana drug used for mānasaroga and apasmāra, with a listed powder dose of 3–8 g. The same official monograph explicitly adds that in certain parts of India, Clitoria ternatea Linn. and Evolvulus alsinoides Linn. are also used as Shankhapushpi. Kew further notes that Convolvulus pluricaulis is currently treated as a synonym of Convolvulus prostratus. That means a rigorous review must report the species actually used in each study, not just the trade name “Shankhpushpi.”

For Vacha, the Ayurvedic Pharmacopoeia identifies the official raw drug as Acorus calamus L. rhizome, with a powder dose of 2–3 g. In contrast, many Chinese experimental and clinical papers use Acorus tatarinowii Schott, which Kew currently treats as a synonym of Acorus verus rather than accepting A. tatarinowii as a separate species. This taxonomic distinction is not academic. It matters because asarone content varies by Acorus taxon/cytotype, and asarone exposure is central to safety and regulatory risk.

Classical Ayurvedic context does support the broad “mind herb” framing, but with important nuance. In the Charaka Samhita, Cikitsasthana 1.3–1.4, Brahmi, Vacha, and Sankhapushpi appear in Aindra Rasayana, and the text also states that “Sankhapuspi is specifically intellect-promoting.” This is a valuable traditional anchor, but it does not by itself establish modern disease efficacy for ADHD, ASD, dementia, or anxiety. Those questions must still be answered by the modern evidence hierarchy.

How these herbs might work

The mechanistic picture is strongest for Bacopa monnieri. Its signature compounds are dammarane-type triterpenoid saponins, collectively referred to as bacosides and bacopasides. Clinical and mechanistic reviews describe several converging actions: cholinergic modulation, antioxidant and anti-inflammatory effects, support of synaptic signaling and neuroplasticity, and modulation of GABAergic and stress-response pathways. StatPearls summarizes that Bacopa has been shown to affect GABAergic signaling, while clinical and preclinical literature links bacosides with memory consolidation and neuroprotection. In practical formulation terms, the useful concept is that Bacopa is not a stimulant; it behaves more like a calm-focus/nootropic adaptogen.

For the Shankhpushpi group, mechanisms depend on the species. In Convolvulus pluricaulis, the literature most often points to alkaloids such as convolamine/convolvine, coumarins such as scopoletin, and flavonoid/polyphenol fractions as candidates for anxiolytic, antioxidant, anti-amnestic, and cholinergic effects. In animal work comparing plant sources marketed as Shankhpushpi, C. pluricaulis showed the strongest nootropic and anxiolytic activity at lower doses than some alternatives.

In Evolvulus alsinoides, preclinical studies point toward antioxidant, anxiolytic, and learning/memory-enhancing actions, with likely contributions from betaine, coumarin derivatives, and flavonoids. The best mechanistic support is still from rodent studies; human biomarker studies are not established.

In Clitoria ternatea, the phytochemical profile is distinct from the Convolvulus/Evolvulus plants. Reviews emphasize triterpenoids, flavonol glycosides, anthocyanins, steroids, and, in the broader phytochemical literature, cyclotides. Cognition-oriented animal studies suggest anticholinesterase, synaptic plasticity, and neuroprotective effects, while anxiolytic/antidepressant-like animal studies suggest broader neurotransmitter modulation. Human neurocognitive evidence, however, remains absent.

For Vacha/Acorus, the best-known compounds are α-asarone and β-asarone, especially in the volatile oil fraction. Experimental literature attributes to Acorus species a mixture of GABAergic/calming, cholinergic, anti-inflammatory, anti-oxidative, pro-neurogenic, and anti-proteinopathy actions, but these mechanisms are entangled with safety because β-asarone is also the compound most implicated in toxicological concern. This is the central trade-off with Vacha: mechanisms look interesting on paper, but commercialization must be constrained by asarone toxicology.

The mechanistic logic can be visualized as follows.

Evidence by life stage and condition

A useful way to read this literature is by age group and target condition, because the evidence is not evenly distributed.

Children and adolescents

For ADHD-related symptoms, Bacopa monnieri is the only one of the three with directly relevant human data. In an open-label study, Dave et al. (2014, Advances in Mind-Body Medicine) treated children with ADHD symptoms using standardized Bacopa extract; the PubMed record and downstream summaries identify this as a pediatric clinical study and sources referencing the paper report a regimen of 225 mg/day for 6 months. This is encouraging but remains low-certainty because of its design.

The stronger pediatric test is Kean et al. (2022, Phytotherapy Research, doi: 10.1002/ptr.7372), a randomized, double-blind, placebo-controlled trial of CDRI-08® Bacopa monnieri in males aged 6–14 years with inattention/hyperactivity. The study used 160 mg/day or 320 mg/day for 16 weeks and found benefits in certain cognitive outcomes, mood, and sleep quality, but effects on core behavioral ADHD measures were less definitive than many consumer summaries imply. The appropriate evidence judgment is therefore promising but not yet practice-changing.

For autism spectrum disorder, I did not identify any human clinical trial of Bacopa monnieri. Recent review literature explicitly states that Bacopa’s efficacy in ASD has not yet been evaluated clinically, although animal data suggest mechanistic plausibility and some rat models show improvement in autism-like behaviors and receptor-pathway markers. This means Bacopa cannot currently be marketed responsibly as an ASD treatment on the basis of human evidence.

For Shankhpushpi, no robust pediatric ADHD or ASD trial was identified for Convolvulus pluricaulis, Evolvulus alsinoides, or Clitoria ternatea used as isolated interventions. The only human study I found for C. pluricaulis was in healthy volunteers aged 16–25 years, not children, and it was a single-group pre-post study rather than an RCT.

For Vacha, I did not identify a pediatric isolated-herb ADHD or ASD trial. Given the asarone safety concerns, the absence of pediatric efficacy data is especially important. Traditional Ayurvedic use in children should not be conflated with modern clinical safety evidence.

Adults with stress, anxiety, and cognitive demands

In non-elderly adults, Bacopa monnieri again leads. Calabrese et al. (2008, Journal of Alternative and Complementary Medicine, doi: 10.1089/acm.2008.0018) studied older adults but included anxiety/depression endpoints and found improvements in delayed recall and reductions in combined state-trait anxiety over 12 weeks with standardized extract. Sathyanarayanan et al. (2013, Psychopharmacology, doi: 10.1007/s00213-013-2978-z) challenged the uniformly positive narrative by reporting that 450 mg/day for 12 weeks in healthy adults did not significantly improve all cognitive outcomes, though there was a trend toward reduced state anxiety. Kumar et al. (2016, Evidence-Based Complementary and Alternative Medicine, doi: 10.1155/2016/4103423) reported improved selected cognitive measures in medical students after 6 weeks of standardized extract. Across trials and reviews, the most defensible interpretation is that Bacopa has real but not dramatic effects, strongest for memory consolidation/delayed recall and calm focus, weaker or more inconsistent for broad executive performance.

For acute stress reactivity, Benson et al. (2014, PubMed indexed) reported an acute cross-over study using 320 mg and 640 mg doses of CDRI-08 on multitasking stress reactivity and mood. Acute studies suggest some short-term anti-stress signal, but most meaningful benefits in the literature appear after chronic dosing over weeks, not after a single dose.

A newer adult stress/sleep trial, Lopresti et al. (2021, Phytomedicine Plus), found that a Bacopa extract did not outperform placebo on every sleep measure but was associated with reductions in cortisol and improvements in some stress-related outcomes. Because this area is growing and methods vary substantially by extract and population, adult stress/anxiety evidence for Bacopa is best described as moderate, extract-specific, and still heterogeneous.

For Shankhpushpi in adults, the modern human evidence is sparse. Amin et al. (2014, Ancient Science of Life, doi: 10.4103/0257-7941.153476) conducted a single-group pre-post study of Convolvulus pluricaulis tablets in 30 healthy volunteers aged 16–25 years over 2 months and reported statistically significant gains in several memory subtests. This is useful as a proof-of-concept, but not enough to support strong marketing claims for working professionals, exam stress, or generalized anxiety.

The best support for Shankhpushpi and anxiety still comes from animal work. Nahata et al. (2009, Pharmaceutical Biology, doi: 10.1080/13880200902822596) found anxiolytic and antioxidant effects for both Evolvulus alsinoides and Convolvulus pluricaulis in rodent models. Malik et al. (2011, Pharmaceutical Biology, doi: 10.3109/13880209.2011.584539) compared plant sources sold as Shankhpushpi and concluded that Convolvulus pluricaulis had the strongest memory-enhancing and anxiolytic activity, while Evolvulus alsinoides and Clitoria ternatea were also active at different dose ranges. These studies are important for species differentiation, but they remain preclinical.

For Vacha/Acorus in adult anxiety, the human signal comes from Bhattacharyya et al. (2011, Indian Journal of Traditional Knowledge), a 33-participant study of generalized anxiety disorder that used 70% hydro-ethanolic extract of Acorus calamus at 500 mg twice daily after meals for 60 days. The study reported significant improvements in anxiety, stress, and depression-related measures. However, it was not a modern placebo-controlled randomized trial, so the evidence level is very low by contemporary standards.

Older adults, cognitive decline, and dementia

For healthy older adults, Bacopa has the clearest support. Morgan and Stevens (2010, Journal of Alternative and Complementary Medicine, doi: 10.1089/acm.2009.0342) randomized older adults over 55 years and found that Bacopa improved memory acquisition and retention over 12 weeks. Calabrese et al. (2008) similarly reported better delayed recall and less anxiety in an elderly cohort. These older-adult RCTs are why Bacopa is often included in evidence-based “healthy ageing cognition” discussions.

For mild cognitive impairment or Alzheimer disease, the picture becomes weaker. The most relevant evidence synthesis is Basheer et al. (2022, systematic review of RCTs), which concluded that there was no convincing difference between Bacopa monnieri and placebo or donepezil in dementia due to Alzheimer disease, based on very low-certainty evidence. This is an important corrective to overenthusiastic marketing: Bacopa is reasonable for memory support in healthy or mildly impaired ageing adults, but the evidence is not strong enough to present it as an established dementia treatment.

For Shankhpushpi and dementia, I did not identify a convincing human RCT using isolated Convolvulus pluricaulis, Evolvulus alsinoides, or Clitoria ternatea. A disease-prevention resource review likewise states that no direct human research is available for dementia. There are interesting preclinical studies, including tau- and amyloid-related models, but the translational bridge has not yet been built.

For Acorus/A. tatarinowii and dementia, the literature is again mostly preclinical or combination-based. The 2024 meta-analysis by Zhang et al. (Frontiers in Pharmacology, doi: 10.3389/fphar.2023.1268000) included 16 RCTs involving 1103 Alzheimer disease participants, but these trials evaluated the combination of Polygala tenuifolia and Acorus tatarinowii, either alone or with standard drugs. The combination plus conventional treatment improved MMSE, ADL, and ADAS-cog versus conventional treatment alone, but the authors rated the evidence as very low to low certainty, and the design does not allow isolation of Acorus as the active driver. For isolated Vacha, direct dementia evidence is therefore still inadequate.

Evidence hierarchy, study doses, and comparative table

The evidence development over time also shows why these herbs should not be treated as equals.

The following table condenses the most decision-relevant differences.

A few formulation implications follow from the table. For Bacopa, the clinically relevant part of the market is standardized extract, not loosely defined powder alone. Reviews and clinical references repeatedly place adult trials in the 300–450 mg/day range and note standardization to roughly 24–55% bacosides, depending on extract design.

For Shankhpushpi, the necessary first step in any serious formulation is species declaration on the label: “Shankhpushpi (Convolvulus pluricaulis)” is not interchangeable with “Shankhpushpi (Clitoria ternatea)”. Given the lack of clear dose-finding RCTs, any standardized-extract strategy should be presented as quality control, not as a proxy for proven efficacy.

For Vacha, the scientifically honest recommendation is different: if the product is meant for broad retail, online commerce, or export, it is generally better to exclude Vacha entirely than to struggle with species authentication, asarone testing, and conflicting regulatory expectations.

Safety, adverse effects, interactions, contraindications, and regulation

For Bacopa monnieri, short-term safety in adults is reasonably reassuring. The most commonly reported adverse effects are gastrointestinal—especially nausea, abdominal cramps, and increased stool frequency—and mild sedation can occur. Bacopa may have cholinergic activity, so StatPearls advises caution with anticholinergic drugs and in conditions where increased cholinergic tone could be problematic, such as bradycardia, gastrointestinal obstruction/peptic ulcer, asthma/COPD, or urinary obstruction. The same source also notes in vitro CYP inhibition involving CYP1A2, CYP2C9, CYP2C19, and CYP3A4, which is a reason for conservative interaction screening in polypharmacy, even though clinically important interactions are not well quantified. Pregnancy/lactation data remain inadequate.

Regulatorily, Bacopa is not an FDA-approved drug for memory, ADHD, anxiety, Alzheimer disease, or any other indication. In the United States it is sold as a dietary ingredient, but FDA warning letters show that when sellers make disease-treatment claims, the products can be considered unapproved drugs or misbranded products. FDA warning letters specifically Bacopa monnieri in this context.

For Shankhpushpi, the human safety database is much thinner than the marketing suggests. The broad take-away is not that it is dangerous; it is that it is under-characterized. Short-term traditional use and small studies do not indicate a major acute safety problem, but high-quality adverse-event reporting is scarce. Because the preclinical literature shows sedative/CNS-depressant and anxiolytic actions, caution is reasonable with sedatives, alcohol, and patients needing high psychomotor performance; because some experimental literature notes interaction with phenytoin, seizure patients should not self-medicate. The strongest safety statement here is simply that species-specific modern safety data are insufficient, so product claims should remain modest.

For Vacha, safety dominates efficacy. Official and quasi-official sources are unusually explicit. 21 CFR §189.110 states that food containing any added calamus, calamus oil, or calamus extract is deemed adulterated in the United States. The EMA/HMPC public statement warns that because of the toxicity of α- and β-asarone, concentrations in herbal medicinal products should be reduced to the minimum possible and diploid varieties are preferred. Toxicological monographs also emphasize the concern around β-asarone. These restrictions do not mean every Acorus preparation is identically hazardous, but they do mean a responsible manufacturer cannot treat Vacha as just another benign “brain herb.” Pregnancy and lactation use should be avoided.

Within India, the regulatory context is different. The Ayurvedic Pharmacopoeia of India gives official monographs for Brahmi, Shankhapushpi, and Vacha, and a Government of India pharmacopoeial source notes that API standards are official under the Drugs & Cosmetics Act framework. That supports their lawful use in classical/proprietary Ayurvedic products within India, but it does not upgrade them to evidence-based modern drug approvals for ADHD, ASD, anxiety disorders, or dementia.

Positioning a product called Brahmi Brain Booster

If the goal is a commercially credible, evidence-aligned product, the name “Brahmi Brain Booster” should map primarily to Bacopa monnieri, not to the historical ambiguity around “Brahmi.” The label and technical dossier should therefore explicitly state “Brahmi (Bacopa monnieri)” and identify the extract standardization. That reduces both pharmacognostic confusion and consumer confusion.

The supported positioning claims are the familiar but carefully bounded ones: supports memory consolidation, delayed recall, attention, calm focus, and stress resilience in adults; and supports healthy cognitive ageing in older adults. These are the claims most defensible from the RCT and meta-analytic literature. They are especially well matched to students, knowledge workers, people under non-clinical stress, and older adults with age-associated memory complaints, provided the marketing language remains in the “supports” frame rather than the “treats/cures disease” frame.

The ADHD opportunity is real but should be handled conservatively. What the evidence supports is a statement such as: “has emerging clinical evidence for supporting attention and behavioral regulation in school-age children; pediatric use should be clinician-supervised and not replace standard evaluation or treatment.” What the evidence does not support is a bold OTC claim that the product treats ADHD. The pediatric evidence is still limited to one open-label study and one RCT with mixed behavioral findings.

The autism positioning should be avoided for now. Across Bacopa, Shankhpushpi, and Vacha, I did not identify human clinical evidence sufficient to support ASD claims. For a serious product team, this is the clearest “do not claim” zone.

A practical formulation strategy would be:

• Lead ingredient: standardized Bacopa monnieri extract with clinically relevant bacoside standardization.
• Adult daily dose: typically 300 mg/day of a clinically studied extract, or a total daily range consistent with trials using 300–450 mg/day, taken with food.
• Pediatric version: only if specifically developed for that market, with dosing anchored to the pediatric literature (225 mg/day in the open-label study or extract-specific dosing such as 160–320 mg/day in the CDRI-08 program), and only under clinician oversight.
• Shankhpushpi add-on: optional only if the species is clearly declared and claims are restricted to traditional use or very cautious support language.
• Vacha: best excluded from general-consumer stock-keeping units, especially where U.S./EU export, food-format use, or aggressive cognition claims are contemplated.

The required disclaimers are not optional. In India, the product should avoid implying replacement of diagnosis or treatment for ADHD, ASD, anxiety disorder, or dementia unless it is being developed under the appropriate regulatory pathway. In the U.S., the product should avoid disease claims altogether; FDA warning letters show that even literature citations used in marketing can be interpreted as evidence of intended disease use. A cautious, compliant disclaimer package would include: not intended to diagnose, treat, cure, or prevent any disease; not a substitute for professional evaluation; consult a physician if pregnant, breastfeeding, taking prescription medicines, or managing neuropsychiatric/cardiovascular disease; discontinue if adverse effects occur. For children, add use only under healthcare supervision.

Gaps in evidence and research priorities

The evidence gaps are not subtle. The strongest gap is the mismatch between traditional reputation and modern trial quality, especially for Shankhpushpi and Vacha. For these two, much of the narrative in popular health content outruns the actual human data. What is needed first is species-authenticated, extract-standardized, placebo-controlled RCTs with transparent adverse-event reporting. Without that, even favorable animal work cannot support precise clinical recommendations.

For Bacopa, the next questions are more specific. The field already has enough adult RCTs to move beyond “does it work at all?” and toward which extract, which dose, which subgroup, and which endpoint. The dementia review shows why this matters: success in healthy ageing and stress does not automatically carry over to symptomatic Alzheimer disease. Similarly, pediatric ADHD evidence needs larger, preregistered, adequately blinded trials with active comparators, teacher-rated outcomes, and long-term safety monitoring.

For autism spectrum disorder, the research agenda is simple because the clinical evidence is close to zero. Before any product or clinician should infer benefit, the field needs pilot human studies that are species-specific, biomarker-informed, and designed around realistic endpoints such as irritability, attention, sleep, anxiety, sensory dysregulation, or caregiver burden, rather than vague “brain tonic” outcomes.

For Vacha/Acorus, no future cognition program is credible without a parallel toxicology/regulatory package. Any serious work should specify species, chemotype/cytotype, asarone content, and purification/manufacturing controls, because these are not edge details—they are the central determinants of whether the product can be used safely and legally.

The final evidence-based ranking is therefore clear. For a web-ready, responsible expository conclusion: Brahmi (Bacopa monnieri) is the clinically strongest and commercially most defensible herb of the three; Shankhpushpi is a promising but botanically messy category with mainly preclinical support; and Vacha is mechanistically interesting but constrained by weak human evidence and serious asarone-related safety/regulatory issues.